Dyne Therapeutics (DYN) News Today $9.70 -0.32 (-3.21%) As of 10:08 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 Time Period Dyne Therapeutics, Inc. (NASDAQ:DYN) Given Average Rating of "Buy" by BrokeragesShares of Dyne Therapeutics, Inc. (NASDAQ:DYN - Get Free Report) have received an average rating of "Buy" from the fifteen analysts that are presently covering the stock, MarketBeat Ratings reports. One equities research analyst has rated the stock with a hold rating, twelve have issued a buy ratMay 6 at 2:27 AM | marketbeat.comDyne Therapeutics, Inc. (NASDAQ:DYN) Shares Bought by ArrowMark Colorado Holdings LLCArrowMark Colorado Holdings LLC increased its position in Dyne Therapeutics, Inc. (NASDAQ:DYN - Free Report) by 3.6% in the 4th quarter, according to its most recent filing with the SEC. The fund owned 932,231 shares of the company's stock after purchasing an additional 32,041 shares during the perMay 5 at 6:47 AM | marketbeat.comMarshall Wace LLP Makes New $577,000 Investment in Dyne Therapeutics, Inc. (NASDAQ:DYN)Marshall Wace LLP purchased a new stake in Dyne Therapeutics, Inc. (NASDAQ:DYN - Free Report) during the fourth quarter, according to its most recent 13F filing with the SEC. The firm purchased 24,501 shares of the company's stock, valued at approximately $577,000. Other institutional investors andMay 5 at 3:35 AM | marketbeat.comDyne Therapeutics, Inc. (NASDAQ:DYN) Receives Average Rating of "Buy" from BrokeragesMay 4 at 2:29 AM | americanbankingnews.comRaymond James Financial Inc. Takes Position in Dyne Therapeutics, Inc. (NASDAQ:DYN)Raymond James Financial Inc. purchased a new stake in Dyne Therapeutics, Inc. (NASDAQ:DYN - Free Report) in the fourth quarter, according to its most recent filing with the SEC. The fund purchased 99,328 shares of the company's stock, valued at approximately $2,340,000. Raymond James Financial Inc.May 2, 2025 | marketbeat.comDyne Therapeutics (NASDAQ:DYN) Shares Up 3.9% - Here's What HappenedDyne Therapeutics (NASDAQ:DYN) Trading 3.9% Higher - What's Next?May 1, 2025 | marketbeat.comPrice T Rowe Associates Inc. MD Decreases Stock Holdings in Dyne Therapeutics, Inc. (NASDAQ:DYN)Price T Rowe Associates Inc. MD decreased its holdings in shares of Dyne Therapeutics, Inc. (NASDAQ:DYN - Free Report) by 8.9% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 2,402,452May 1, 2025 | marketbeat.comFirst Light Asset Management LLC Has $9.91 Million Stock Holdings in Dyne Therapeutics, Inc. (NASDAQ:DYN)First Light Asset Management LLC decreased its position in Dyne Therapeutics, Inc. (NASDAQ:DYN - Free Report) by 66.6% during the 4th quarter, according to its most recent filing with the SEC. The institutional investor owned 420,431 shares of the company's stock after selling 836,854 shares durinApril 30, 2025 | marketbeat.comLegal & General Group Plc Has $1.61 Million Stock Position in Dyne Therapeutics, Inc. (NASDAQ:DYN)Legal & General Group Plc lessened its holdings in Dyne Therapeutics, Inc. (NASDAQ:DYN - Free Report) by 38.7% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 68,465 shares of the company's stock after selling 43,192April 28, 2025 | marketbeat.comDyne Therapeutics, Inc. (NASDAQ:DYN) Shares Sold by Adage Capital Partners GP L.L.C.Adage Capital Partners GP L.L.C. lessened its position in Dyne Therapeutics, Inc. (NASDAQ:DYN - Free Report) by 18.9% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 1,950,000 shares of the company's stoApril 27, 2025 | marketbeat.comDyne Therapeutics (DYN) to Release Quarterly Earnings on ThursdayDyne Therapeutics (NASDAQ:DYN) will be releasing its Q1 2025 earnings before the market opens on Thursday, May 1. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2025-5-1-dyne-therapeutics-inc-stock-1/)April 26, 2025 | marketbeat.comIs Dyne Therapeutics Inc. (NASDAQ:DYN) the Most Promising Small-Cap Stock According to Analysts?April 26, 2025 | insidermonkey.comEC grants orphan drug designation to Dyne Therapeutics’ DMD therapyApril 25, 2025 | finance.yahoo.comDyne Therapeutics stock rises on orphan drug statusApril 24, 2025 | au.investing.comDyne Therapeutics receives EMA orphan drug designation for DYNE-251April 24, 2025 | markets.businessinsider.comDyne Therapeutics Receives European Medicines Agency (EMA) Orphan Drug Designation for DYNE-251 in Duchenne Muscular DystrophyApril 24, 2025 | globenewswire.comDyne Therapeutics (NASDAQ:DYN) Shares Up 4% - What's Next?Dyne Therapeutics (NASDAQ:DYN) Stock Price Up 4% - Should You Buy?April 23, 2025 | marketbeat.comJump Financial LLC Takes Position in Dyne Therapeutics, Inc. (NASDAQ:DYN)Jump Financial LLC acquired a new position in Dyne Therapeutics, Inc. (NASDAQ:DYN - Free Report) in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund acquired 50,911 shares of the company's stock, valued at approximately $1,199April 23, 2025 | marketbeat.comWhy Sarepta Therapeutics And Other Genetics Stocks Just Got A Sizable BoostApril 21, 2025 | msn.comDyne Therapeutics, Inc.: Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)April 18, 2025 | finanznachrichten.deDyne Therapeutics (NASDAQ:DYN) Stock Price Up 6.8% - Here's What HappenedDyne Therapeutics (NASDAQ:DYN) Trading Up 6.8% - Here's What HappenedApril 17, 2025 | marketbeat.comPetri Dish: Roche unloads drug to Cambridge biotech, Cue and Boehringer link upApril 17, 2025 | bizjournals.comDyne Therapeutics appoints Ranade as CBO, Batra as CSOApril 16, 2025 | markets.businessinsider.comDyne Therapeutics Announces Chief Business Officer and Chief Scientific Officer AppointmentsApril 15, 2025 | globenewswire.comFmr LLC Sells 1,029,766 Shares of Dyne Therapeutics, Inc. (NASDAQ:DYN)Fmr LLC decreased its position in Dyne Therapeutics, Inc. (NASDAQ:DYN - Free Report) by 11.4% during the 4th quarter, according to its most recent filing with the SEC. The institutional investor owned 7,996,931 shares of the company's stock after selling 1,029,766 shares during the period. Fmr LLCApril 15, 2025 | marketbeat.comDyne Therapeutics (DYN) Receives a Buy from Piper SandlerApril 14, 2025 | markets.businessinsider.comDyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)April 14, 2025 | globenewswire.comFederated Hermes Inc. Lowers Stake in Dyne Therapeutics, Inc. (NASDAQ:DYN)Federated Hermes Inc. cut its position in Dyne Therapeutics, Inc. (NASDAQ:DYN - Free Report) by 13.2% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 1,056,241 shares of the company'sApril 11, 2025 | marketbeat.comDyne Therapeutics (NASDAQ:DYN) Stock Price Down 2.9% - Here's What HappenedDyne Therapeutics (NASDAQ:DYN) Shares Down 2.9% - Here's WhyApril 10, 2025 | marketbeat.comInsider Purchases Worth US$1.06m See Losses As Dyne Therapeutics Market Value Drops To US$770mApril 10, 2025 | finance.yahoo.comDyne Therapeutics, Inc. (NASDAQ:DYN) Receives Consensus Recommendation of "Buy" from AnalystsShares of Dyne Therapeutics, Inc. (NASDAQ:DYN - Get Free Report) have earned a consensus recommendation of "Buy" from the fifteen ratings firms that are covering the company, Marketbeat Ratings reports. One investment analyst has rated the stock with a hold recommendation, twelve have assigned aApril 10, 2025 | marketbeat.comDyne Therapeutics (NASDAQ:DYN) Sets New 12-Month Low - Should You Sell?Dyne Therapeutics (NASDAQ:DYN) Reaches New 52-Week Low - Should You Sell?April 9, 2025 | marketbeat.comVanguard Group Inc. Sells 160,211 Shares of Dyne Therapeutics, Inc. (NASDAQ:DYN)Vanguard Group Inc. cut its position in Dyne Therapeutics, Inc. (NASDAQ:DYN - Free Report) by 2.3% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 6,703,926 shares of the company's stock after selling 16April 9, 2025 | marketbeat.com131,200 Shares in Dyne Therapeutics, Inc. (NASDAQ:DYN) Purchased by Springhill Fund Asset Management HK Co LtdSpringhill Fund Asset Management HK Co Ltd bought a new stake in Dyne Therapeutics, Inc. (NASDAQ:DYN - Free Report) in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm bought 131,200 shares of the company's stock, valued at approximApril 8, 2025 | marketbeat.comDyne Therapeutics, Inc. (NASDAQ:DYN) Shares Purchased by Trexquant Investment LPTrexquant Investment LP grew its stake in shares of Dyne Therapeutics, Inc. (NASDAQ:DYN - Free Report) by 95.6% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 125,378 shares of thApril 8, 2025 | marketbeat.comNorges Bank Makes New Investment in Dyne Therapeutics, Inc. (NASDAQ:DYN)Norges Bank bought a new stake in shares of Dyne Therapeutics, Inc. (NASDAQ:DYN - Free Report) during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund bought 950,104 shares of the company's stock, valued at approximately $22,3April 8, 2025 | marketbeat.comDyne Therapeutics, Inc. (NASDAQ:DYN) Shares Acquired by Schroder Investment Management GroupSchroder Investment Management Group boosted its holdings in Dyne Therapeutics, Inc. (NASDAQ:DYN - Free Report) by 63.3% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 147,002 shares of the company's stockApril 7, 2025 | marketbeat.comDyne Therapeutics (NASDAQ:DYN) Trading 6.1% Higher - What's Next?Dyne Therapeutics (NASDAQ:DYN) Trading 6.1% Higher - Here's What HappenedApril 4, 2025 | marketbeat.comPrudential Financial Inc. Decreases Stock Position in Dyne Therapeutics, Inc. (NASDAQ:DYN)Prudential Financial Inc. decreased its position in Dyne Therapeutics, Inc. (NASDAQ:DYN - Free Report) by 43.1% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 145,510 shares of the company's stock aftApril 3, 2025 | marketbeat.comOversold Conditions For Dyne TherapeuticsApril 3, 2025 | nasdaq.comDyne Therapeutics (NASDAQ:DYN) Hits New 52-Week Low - Time to Sell?Dyne Therapeutics (NASDAQ:DYN) Sets New 1-Year Low - Should You Sell?April 2, 2025 | marketbeat.comDyne Therapeutics (NASDAQ:DYN) Shares Gap Down - Should You Sell?Dyne Therapeutics (NASDAQ:DYN) Shares Gap Down - Time to Sell?April 1, 2025 | marketbeat.comSensei Biotherapeutics (SNSE) Gets a Buy from OppenheimerMarch 30, 2025 | markets.businessinsider.comDyne Therapeutics (NASDAQ:DYN) Trading 5.4% Higher - What's Next?Dyne Therapeutics (NASDAQ:DYN) Trading 5.4% Higher - Should You Buy?March 28, 2025 | marketbeat.comDyne Therapeutics (NASDAQ:DYN) Reaches New 12-Month Low - Here's What HappenedDyne Therapeutics (NASDAQ:DYN) Sets New 1-Year Low - Should You Sell?March 27, 2025 | marketbeat.comDyne Therapeutics (NASDAQ:DYN) Stock Price Down 4.2% - Should You Sell?Dyne Therapeutics (NASDAQ:DYN) Shares Down 4.2% - Should You Sell?March 26, 2025 | marketbeat.comDyne Therapeutics Appoints Erick J. Lucera as Chief Financial Officer to Support Late-Stage Clinical ProgramsMarch 22, 2025 | nasdaq.comDyne Therapeutics (NASDAQ:DYN) Given New $17.00 Price Target at JPMorgan Chase & Co.JPMorgan Chase & Co. decreased their price objective on Dyne Therapeutics from $18.00 to $17.00 and set a "neutral" rating for the company in a research note on Friday.March 22, 2025 | marketbeat.comDyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Chief Financial OfficerMarch 20, 2025 | globenewswire.comDyne Therapeutics Announces Appointment of Erick J. Lucera as Chief Financial OfficerMarch 20, 2025 | globenewswire.com Get Dyne Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for DYN and its competitors with MarketBeat's FREE daily newsletter. Email Address DYN Media Mentions By Week DYN Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. DYN News Sentiment▼1.250.65▲Average Medical News Sentiment DYN News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. DYN Articles This Week▼77▲DYN Articles Average Week Get Dyne Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for DYN and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Grifols News Today Elanco Animal Health News Today Krystal Biotech News Today Vaxcyte News Today Cytokinetics News Today Rhythm Pharmaceuticals News Today Avidity Biosciences News Today Ultragenyx Pharmaceutical News Today Akero Therapeutics News Today Arcellx News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:DYN) was last updated on 5/7/2025 by MarketBeat.com Staff From Our PartnersElon’s Terrifying Warning Forces Trump To Take ActionElon Musk has avoided two major financial crises before. He pulled Tesla and SpaceX back from the brink of col...American Hartford Gold | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredTrump’s Bitcoin Reserve is No Accident…Bryce Paul believes this is the #1 coin to buy right now The catalyst behind this surge is a massive new b...Crypto 101 Media | SponsoredShocking AI play that’s beats Nvidia by a country mileYou’ve seen the headlines about Nvidia. Now Tim Sykes is sounding the alarm — because what CEO Jensen Huang is...Timothy Sykes | SponsoredVirtually Limitless Energy?A radical energy breakthrough could change everything. Scientists at MIT and a stealth startup may have discov...Stansberry Research | SponsoredElon just did WHAT!?As you may recall, Biden and the Fed were working on a central bank digital currency, or CBDC. Had they got...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Dyne Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Dyne Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy DYN Stock Free DYN Stock Alerts